Hyperacidity, GERD, and ulcers:

Indications for: CARAFATE

Short-term (up to 8 weeks) treatment of active duodenal ulcer. Maintenance of healed duodenal ulcers (tabs only).

Adult Dosage:

Active: 1g 4 times daily on an empty stomach for 4–8 weeks. Maintenance: 1g 2 times daily.

Children Dosage:

Not established.

CARAFATE Warnings/Precautions:

Susp: administer by oral route only; do not give intravenously. Monitor for glycemia in diabetic patients. Chronic renal failure. Dialysis. Tabs: swallowing impairment (eg, recent or prolonged intubation, tracheostomy, history of aspiration, dysphagia, others). Pregnancy (Cat.B). Nursing mothers.

CARAFATE Classification:

Cytoprotective agent.

CARAFATE Interactions:

Avoid antacids within 30mins of dosing. May reduce absorption of tetracyclines, quinidine, levothyroxine, phenytoin, cimetidine, digoxin, ciprofloxacin, norfloxacin, ketoconazole, ranitidine, theophylline; dose concomitant drugs 2hrs before sucralfate. Additive aluminum load with aluminum-containing antacids. Monitor warfarin.

Adverse Reactions:


Drug Elimination:


How Supplied:

Tabs—100; Susp—14oz